Insight Molecular Diagnostics (IMDX) Non Operating Investment Income (2018 - 2023)
Insight Molecular Diagnostics' (IMDX) quarterly Non Operating Investment Income came in at -$69000.0 in Q4 2023, down 592.86% year-on-year from $14000.0 in Q4 2022, and up 22.47% quarter-over-quarter from -$89000.0 in Q3 2023.
Insight Molecular Diagnostics (IMDX) Non Operating Investment Income (2018 - 2023) Analysis & Trends
Insight Molecular Diagnostics has disclosed Non Operating Investment Income across 6 years of filings, most recently posting -$69000.0 for Q4 2023.
- Non Operating Investment Income for Q4 2023 came in at -$69000.0, down 592.86% year-over-year; the trailing twelve-month figure through Dec 2023 was -$61000.0 (up 87.05% YoY), and the FY2023 annual result was -$61000.0, up 87.05% from the prior year.
- Non Operating Investment Income came in at -$69000.0 for Q4 2023 at Insight Molecular Diagnostics, up from -$89000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $315000.0 in Q4 2020 to a low of -$330000.0 in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$21500.0 (2021), against an average of -$2700.0.
- Peak annual rise in Non Operating Investment Income reached 981.25% in 2021, while the deepest fall reached 790.0% in 2021.
- Insight Molecular Diagnostics' Non Operating Investment Income stood at -$36000.0 in 2019, then surged by 975.0% to $315000.0 in 2020, then plunged by 106.03% to -$19000.0 in 2021, then soared by 173.68% to $14000.0 in 2022, then sank by 592.86% to -$69000.0 in 2023.
- The last three Non Operating Investment Income figures came in at -$69000.0 (Q4 2023), -$89000.0 (Q3 2023), and -$24000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,010.71 Bn | 30,010.25 Bn | 1.11 Bn | - |
| 2 | Thermo Fisher Scientific | 179.46 Bn | 176.21 Bn | 7.74 Bn | - |
| 3 | Danaher | 130.33 Bn | 124.64 Bn | 3.59 Bn | - |
| 4 | Idexx Laboratories | 44.44 Bn | 44.24 Bn | 722.74 Mn | - |
| 5 | Agilent Technologies | 37.27 Bn | 35.46 Bn | 990.00 Mn | - |
| 6 | Iqvia Holdings | 30.70 Bn | 28.73 Bn | 1.36 Bn | - |
| 7 | Natera | 30.59 Bn | 29.49 Bn | 696.04 Mn | - |
| 8 | Illumina | 24.86 Bn | 23.71 Bn | 721.00 Mn | - |
| 9 | Mettler Toledo International | 23.06 Bn | 23.00 Bn | 555.82 Mn | - |
| 10 | Insight Molecular Diagnostics | 4.44 Mn | -24.49 Mn | 15,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -69,000.00 |
| Dec 31, 2023 | -69,000.00 |
| Sep 30, 2023 | -89,000.00 |
| Sep 30, 2023 | -89,000.00 |
| Jun 30, 2023 | -24,000.00 |
| Jun 30, 2023 | -24,000.00 |
| Mar 31, 2023 | 121,000.00 |
| Mar 31, 2023 | 121,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Sep 30, 2022 | -160,000.00 |
| Sep 30, 2022 | -160,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | -330,000.00 |
| Mar 31, 2022 | -330,000.00 |
| Dec 31, 2021 | -19,000.00 |
| Dec 31, 2021 | -19,000.00 |
| Sep 30, 2021 | -138,000.00 |
| Sep 30, 2021 | -138,000.00 |